Hospitalization period and direct medical cost in patients using warfarin or novel oral anti‐coagulants after a cerebral embolism
- 154 Downloads
Background Warfarin has been used in Japan for a long time in patients after cerebral embolism to prevent recurrence. Recently, several novel oral anti-coagulants (NOACs) have been approved for use and are gradually replacing warfarin. However, it remains unclear whether warfarin and other NOACs differ from each other with respect to drug costs and length of stay (LOS) during treatment in Japan. Objective To assess differences in LOS and direct medical cost between patients after cerebral embolism treated with warfarin and those treated with NOACs. Setting Thirteen acute care hospitals in Japan. Method For hospitalized patients with cerebral embolisms who were treated with NOACs and/or warfarin between April 2012 and March 2014, we assessed LOS for patients with warfarin and NOAC using log-rank test, and stratified proportional hazard regression. Also, we assess direct medical cost using paired-t test. Main Outcome measure LOS and medical cost after first treatment with warfarin and NOAC. Results The median LOS for NOACs-treated patients was 12.5 days and that for warfarin treated patients was 19.0 days while the corresponding mean medical costs were USD 7151 ± 6228 [JPY 736,546 ± 641,437] and USD 8950 ± 5891 [JPY 921,830 ± 606,765]. The drug cost for NOACs-treated patients was higher but costs for laboratory-test and hospitalization were lower than those for warfarin-treated patients. Conclusions For NOAC-treated patients, LOS was shorter, and medical cost during hospitalization tended to be lower than those for warfarin-treated patients, whereas NOACs prices were higher than warfarin price.
KeywordsDOAC Hospitalization period Japan Medical cost NOAC Novel oral anti-coagulants Warfarin
This research was not supported by any external funding.
Conflicts of interest
Tomohide Akase has no conflicts of interest to declare. Masami Morita (M.M) was an employee at Shionogi & Co., Ltd at the time of performing this research. Takanori Tsuchiya (T.T) is an employee for Pfizer Japan Inc. However, the roles of M.M and T.T in these companies were not related to this research at the time of conducting the research.
- 1.MHLW. Summary of DPC (Diagnosis Procedure Combination) system and its basic concept. In: Ministry of health Labour and Welfare. 2016. http://www.mhlw.go.jp/stf/shingi/2r985200000105vx-att/2r98520000010612.pdf. Accessed 18 June 2018.
- 2.Akase T, Tsuchiya T, Kobayashi M. Study on lengths of stay and use of pharmaceutical products on DPC date in a hospital group. J Jpn Assoc Health Care Adm. 2016;9(1):57–63 (in Japanese).Google Scholar
- 6.Kagayama K, Ono S. Duration of clinical developments and approval reviews—based on survey results in 2014. Jpn J Clin Pharmacol Ther. 2015;46(Suppl):S261 (in Japanese).Google Scholar
- 7.PMDA. List of Approved Products. In: New Drug. 2016. http://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html of subordinate document. Accessed 18th June 2018.
- 8.MHLW. Factor analysis of medical expenditure increasing. In: Cabinet Office, Government Of Japan. 2016. http://www5.cao.go.jp/keizai-shimon/kaigi/special/reform/wg1/280915/shiryou2-1.pdf. Accessed 1 October 2018 (in Japanese).
- 9.Tanaka K, Takashima S, Yaguchi Y, Dougu N, Nukui T, Konishi H, et al. Changes in clinical practice after the introduction of non-vitamin K antagonist oral anticoagulants (NOAC) for patients with non-valvular atrial fibrillation. Cereb Blood Flow Metab. 2015;26(2):57–62 (in Japanese).CrossRefGoogle Scholar
- 14.Srvices HICRR. Master list for drug. In: Health Insurance Claims Review & Reimbursement Srvices. 2012. http://www.ssk.or.jp/seikyushiharai/tensuhyo/kihonmasta/h24/kihonmasta_04.html. Accessed 18 June 2018.
- 15.Srvices HICRR. Master list for medical examination-treatment. In: Health Insurance Claims Review & Reimbursement Srvices. 2012. http://www.ssk.or.jp/seikyushiharai/tensuhyo/kihonmasta/h24/kihonmasta_01.html. Accessed 18 June 2018.
- 16.OECD. PPPs and exchange rates. In: OECD.stat. OECD. https://stats.oecd.org/Index.aspx?DataSetCode=SNA_TABLE4. Accessed 18 June 2018.
- 19.Hoshino T, Okada K. Estimation of causal effect using propensity score methods in clinical medicine, epidemiology, pharmacoepidemiology and public health; A review. J Natl Inst Public Health. 2006;55(3):230–43 (in Japanese).Google Scholar
- 27.Sterne JA, Bodalia PN, Bryden PA, Davies PA, Lopez-Lopez JA, Okoli GN, et al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess. 2017;21(9):1–386.CrossRefGoogle Scholar
- 28.Hori M, Koretsune Y, Yasaka M, Shimada I, Fukuda T. Health economic analysis of dabigatran etexilate for stroke prevention in patient with nonvalvular atrial fibrillation. Pharma Medica. 2011;29(4):151–64 (in Japanese).Google Scholar
- 30.Okumura K, Kamae I, Hashimoto Y, Koretsune Y, Tanahashi N, Murata T, et al. Estimation of cost saving effect for non-valvular artrial fibrillation patient treated by apixaban. Med Drug J. 2014;50(3):993–1003 (in Japanese).Google Scholar
- 31.Hori M, Koretsune Y, Yasaka M, Murata T, Fukaya T, Shibahara T. Burden of cardiovascular event for patient with artrial fibrillation: health economic assessment of dabigatran and warfarin. Pharma Medica. 2015;33(2):87–95 (in Japanese).Google Scholar